Proliferative Diabetic Retinopathy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Global Proliferative Diabetic Retinopathy Market Size and it is segmented By Treatment Type (Anti-VEGF Agents, Corticosteroids, Laser Surgery, Others) and Geography.

Proliferative Diabetic Retinopathy Market Size

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Proliferative Diabetic Retinopathy Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 9.40 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Proliferative Diabetic Retinopathy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Proliferative Diabetic Retinopathy Market Analysis

The Proliferative Diabetic Retinopathy Market is expected to register a CAGR of 9.4% during the forecast period. Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative diabetic retinopathy is the most advanced stage of diabetic retinopathy which is characterized by the growth of new vessels on the surface of the retina. Some of the signs and symptoms are progressive loss of vision, fine to severe loops of new vessels that may grow on the optic disc and these new vessels may leak and resulting in retinal edema and so on. The major risk factors for proliferative diabetic retinopathy (PDR) include the duration of diabetes, for 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of proliferative diabetic retinopathy (PDR).

According to the International Agency for the Prevention of Blindness, low- and middle-income countries account for approximately 75% of the global diabetes burden, yet many people are ill-equipped to properly identify, treat and manage this disease. Furthermore, as per the study published in the Ophthalmological Journal, estimates diabetic retinopathy affects 1 in 3 people with diabetes and by the year 2040, diabetes is projected to affect 642 million adults.

Growth in the geriatric population increases the prevalence of diabetes and diabetic retinopathy and the availability of advanced technology and minimally invasive laser technique are the key driving factors in the proliferative diabetic retinopathy market.

Proliferative Diabetic Retinopathy Market Trends

This section covers the major market trends shaping the Proliferative Diabetic Retinopathy Market according to our research experts:

Anti-VEGF Agents Segment is Expected to Witness a Healthy CAGR

The recent research studies suggest that in cases of proliferative diabetic retinopathy, high levels of the vascular endothelial growth factor being detected in fibrovascular tissues of eyes of diabetic patients have prompted the use of anti-VEGF as the most effective and efficient management method. According to the International Agency for the Prevention of Blindness, by the year 2040, about 224 million (35%) people worldwide will have some form of diabetic retinopathy, in addition, 70 million (11%) people will have vision-threatening diabetic retinopathy.

Anti-VEGF agents segment holds a significant market share in the proliferative diabetic retinopathy market and is anticipated to show a similar trend over the forecast period due to effective treatment which resulted in improvements in visual acuity of patients with proliferative diabetic retinopathy when comparative to improvements observed in treatment by using corticosteroids.

Rising prevalence of diabetic retinopathy and the availability of advanced technology are the key driving factors in the Anti-VEGF agent's segment.

Proliferative Diabetic Retinopathy key trend 1

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global proliferative diabetic retinopathy market due to rising prevalence of diabetes and diabetic retinopathy and availability of advanced technology and minimally invasive laser technique in this region. According to the Centers for Disease Control and Prevention, approximately 4.2 million adults had diabetic retinopathy and 655,000 had vision-threatening diabetic retinopathy. Furthermore, increasing healthcare expenditure and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Proliferative Diabetic Retinopathy Market 2

Proliferative Diabetic Retinopathy Industry Overview

The Proliferative Diabetic Retinopathy Market is consolidated and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Novartis AG, Regeneron Pharmaceuticals Inc, Allergan Plc, Hoffmann-La Roche (Genentech), Oxurion NV, Alimera Sciences, BCN Peptides, Glycadia Pharmaceuticals and Kowa Group.

Proliferative Diabetic Retinopathy Market Leaders

  1. Novartis AG

  2. Regeneron Pharmaceuticals Inc

  3. Allergan Plc

  4. Hoffmann-La Roche (Genentech)

  5. Oxurion NV

*Disclaimer: Major Players sorted in no particular order

Proliferative Diabetic Retinopathy landscape
Need More Details on Market Players and Competitors?
Download PDF

Proliferative Diabetic Retinopathy Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Diabetes Increases Risk of Diabetic Retinopathy
    • 4.2.2 Availability of Advanced Technology and Minimally Invasive Laser Technique
  • 4.3 Market Restraints
    • 4.3.1 Extended Approval Time for Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Anti-VEGF Agents
    • 5.1.2 Corticosteroids
    • 5.1.3 Laser Surgery
    • 5.1.4 Others
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novartis AG
    • 6.1.2 Regeneron Pharmaceuticals Inc
    • 6.1.3 Allergan Plc
    • 6.1.4 Hoffmann-La Roche (Genentech)
    • 6.1.5 Oxurion NV
    • 6.1.6 Alimera Sciences
    • 6.1.7 BCN Peptides
    • 6.1.8 Glycadia Pharmaceuticals
    • 6.1.9 Kowa Group
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Proliferative Diabetic Retinopathy Industry Segmentation

Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative Diabetic Retinopathy Market is segmented By Treatment Type and Geography.

By Treatment Type Anti-VEGF Agents
Corticosteroids
Laser Surgery
Others
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Proliferative Diabetic Retinopathy Market Research FAQs

The Proliferative Diabetic Retinopathy Market is projected to register a CAGR of 9.40% during the forecast period (2024-2029)

Novartis AG, Regeneron Pharmaceuticals Inc, Allergan Plc, Hoffmann-La Roche (Genentech) and Oxurion NV are the major companies operating in the Proliferative Diabetic Retinopathy Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Proliferative Diabetic Retinopathy Market.

The report covers the Proliferative Diabetic Retinopathy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Proliferative Diabetic Retinopathy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Proliferative Diabetic Retinopathy Industry Report

Statistics for the 2024 Proliferative Diabetic Retinopathy market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Proliferative Diabetic Retinopathy analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Proliferative Diabetic Retinopathy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)